Though patient response to PD-1/PD-L1 checkpoint inhibition remains difficult to predict, biomarkers for positive outcomes in anti-PD-L1 therapy include IHC for tumor PD-L1 and tumor mutational burden [31], while biomarkers for anti-TGF-β are unknown. This evidence concerns the gene TGFB1 and neoplasm.